TY - JOUR
T1 - The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
AU - Guo, Yuchen
AU - Lin, Chu
AU - Cai, Xiaoling
AU - Wu, Han
AU - Yan, Jingya
AU - Li, Zonglin
AU - Jiao, Ruoyang
AU - Bai, Shuzhen
AU - Yang, Wenjia
AU - Lv, Fang
AU - Liu, Geling
AU - Yang, Xiaolin
AU - Ji, Linong
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/10/18
Y1 - 2024/10/18
N2 - The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated. We searched PubMed, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrial.gov website from the inception to April 2024 and included 129 randomized controlled trials (RCTs) of AOMs. When compared with placebo, every 5 kg weight reduction mediated by AOMs was associated with the reduced risks of 3-point major adverse cardiovascular events (relative risk [RR] 0.72, 95% confidence interval [CI] 0.60–0.85), myocardial infarction (RR 0.75, 95% CI 0.60–0.95), stroke (RR 0.60, 95% CI 0.42–0.85), and heart failure (RR 0.71, 95% CI 0.54–0.95). As for glucagon-like peptide 1 receptor agonist (GLP-1RA)-users, similar cardiovascular benefits were also observed with 5 kg weight loss. This study indicated that the weight reductions mediated by AOMs were associated with cardiovascular benefits observed in AOM-users.
AB - The association between anti-obesity medications (AOMs) as well as their weight-loss effects and cardiovascular outcomes need to be comprehensively investigated. We searched PubMed, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrial.gov website from the inception to April 2024 and included 129 randomized controlled trials (RCTs) of AOMs. When compared with placebo, every 5 kg weight reduction mediated by AOMs was associated with the reduced risks of 3-point major adverse cardiovascular events (relative risk [RR] 0.72, 95% confidence interval [CI] 0.60–0.85), myocardial infarction (RR 0.75, 95% CI 0.60–0.95), stroke (RR 0.60, 95% CI 0.42–0.85), and heart failure (RR 0.71, 95% CI 0.54–0.95). As for glucagon-like peptide 1 receptor agonist (GLP-1RA)-users, similar cardiovascular benefits were also observed with 5 kg weight loss. This study indicated that the weight reductions mediated by AOMs were associated with cardiovascular benefits observed in AOM-users.
KW - Cardiovascular medicine
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=85207794636&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2024.110867
DO - 10.1016/j.isci.2024.110867
M3 - Article
AN - SCOPUS:85207794636
SN - 2589-0042
VL - 27
JO - iScience
JF - iScience
IS - 10
M1 - 110867
ER -
